Analyst Ratings For Ultragenyx Pharmaceutical (NASDAQ:RARE)
Today, Stifel Nicolaus reiterated its Buy rating on Ultragenyx Pharmaceutical (NASDAQ:RARE) with a price target of $74.00.
Some recent analyst ratings include
- 2/21/2018-Stifel Nicolaus Reiterated Rating of Buy .
- 1/22/2018-Evercore ISI Upgrade from a “In-Line ” rating to a ” Outperform” rating.
- 1/17/2018-Credit Suisse Group initiated coverage with a Outperform rating.
- 12/15/2017-Raymond James Financial Reiterated Rating of Buy.
- 12/4/2017-Jefferies Group Upgrade from a “Hold ” rating to a ” Buy” rating.
Recent Insider Trading Activity For Ultragenyx Pharmaceutical (NASDAQ:RARE)
Ultragenyx Pharmaceutical (NASDAQ:RARE) has insider ownership of 9.20% and institutional ownership of 85.01%.
- On 8/28/2017 Emil D Kakkis, CEO, bought 7,500 with an average share price of $52.52 per share and the total transaction amounting to $393,900.00.
- On 5/26/2017 Theodore Alan Huizenga, VP, sold 480 with an average share price of $57.46 per share and the total transaction amounting to $27,580.80.
- On 3/9/2017 Theodore Alan Huizenga, Insider, sold 2,500 with an average share price of $86.34 per share and the total transaction amounting to $215,850.00.
- On 3/2/2017 Shalini Sharp, CFO, sold 12,000 with an average share price of $90.10 per share and the total transaction amounting to $1,081,200.00.
- On 2/27/2017 Shalini Sharp, CFO, sold 12,000 with an average share price of $80.14 per share and the total transaction amounting to $961,680.00.
- On 12/5/2016 William Aliski, Director, sold 6,000 with an average share price of $78.19 per share and the total transaction amounting to $469,140.00.
- On 11/9/2016 Shalini Sharp, CFO, sold 24,000 with an average share price of $71.20 per share and the total transaction amounting to $1,708,800.00.
Recent Trading Activity for Ultragenyx Pharmaceutical (NASDAQ:RARE)
Shares of Ultragenyx Pharmaceutical closed the previous trading session at 45.02 down -3.16 6.56% with shares trading hands.
